36 results about "Obstructive chronic bronchitis" patented technology

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

1. The name of the design product: water negative ion device. 2. The use of the design product: for air purification and disinfection, auxiliary treatment of chronic bronchitis and non-acute insomnia. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective drawing.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

Apparatuses, systems and methods are provided for treating pulmonary tissues via delivery of energy, generally characterized by high voltage pulses, to target tissue using a pulmonary tissue modification system (e.g., an energy delivery catheter system). Example pulmonary tissues include, without limitation, the epithelium (the goblet cells, ciliated pseudostratified columnar epithelial cells, and basal cells), lamina propria, submucosa, submucosal glands, basement membrane, smooth muscle, cartilage, nerves, pathogens resident near or within the tissue, or a combination of any of these. The system may be used to treat a variety of pulmonary diseases or disorders such as or associated with COPD (e.g., chronic bronchitis, emphysema), asthma, interstitial pulmonary fibrosis, cystic fibrosis, bronchiectasis, primary ciliary dyskinesia (PCD), acute bronchitis and / or other pulmonary diseases or disorders.

The present invention relates to novel pyrrolidinium compounds, stereoisomers, hydrates or solvates thereof, which exhibit excellent binding capacity and antagonistic activity to muscarinic receptors, in particular muscarinic M3 receptors. The compounds of the present invention are useful in the treatment of muscarinic acetylcholine receptor mediated diseases, such as hyperhidrosis, excessive salivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder, gastroesophageal reflux disease, irritable bowel syndrome, and the like.

The invention discloses a Tibetan medicine Banjiaojiaopian pellet preparation, which comprises raw materials and auxiliary materials, the raw materials comprise the following components: gentiana algida, agilawood, choerospondias axillaris, white sandalwood, myristica fragrans, tabasheer, alpine horseradish, costus root, fructus chebulae, fructus terminaliae billericae, emblic leafflower fruit, tinospora sinensis merr, corydalis impatiens, clove and liquorice, and the auxiliary materials comprise an adhesive and a filler microcrystalline cellulose; the technological parameters for preparing the pellet preparation by adopting centrifugal granulation are as follows: the liquid spraying speed is 50ml / min, the number of revolutions of a turntable is 30r / min, and the air inlet temperature is 75 DEG C. Compared with traditional pills, the pellet preparation provided by the invention has the advantages of high dissolution rate, obviously improved bioavailability, reliable drug effect, accurate taking dosage, stable quality, low cost, good treatment effect, fine production process, good reproducibility, good quality controllability, high industrial production efficiency and wide application range.

The invention relates to the technical field of traditional Chinese medicine or food, and provides an application of a traditional Chinese medicine composition in preparation of a product for relieving and / or preventing lung heat and fluid impairment syndrome, the composition comprises the following components: orange peel, honeysuckle, mint, forsythia leaf, reed rhizome, platycodon grandiflorum, boat-fruited sterculia seed, lily, momordica grosvenori and almond. The composition provided by the invention has a remarkable effect of preventing chronic upper respiratory infection, a remarkable effect of treating oral ulcer caused by excessive internal heat, a remarkable effect of treating chronic pharyngolaryngitis and a remarkable effect of treating chronic bronchitis, and can be used for preparing products for relieving and / or preventing and treating lung heat and fluid impairment syndromes.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

Disclosed are compositions and methods for treating, amelioriating, reversing and / or preventing (acting as a prophylaxis): a respiratory condition involving an infection or an inflammation, or any lung condition involving inflammation or infection, e.g., of a respiratory mucosa, and / or an infection or an inflammation of an underlying muscle of the respiratory tract; or, an asthma; a bronchitis; a sinusitis or rhinosinusitis; an infection of a sinus; chronic obstructive airway disease; emphysema; chronic bronchitis; pneumonia; or, a bronchiectasis. In alternative embodiments, the therapeutic combination comprises an orally administered Amphotericin B or equivalent antifungal alone, or a combination of Amphotericin B and: one antibiotic; two antibiotics; three antibiotics; or, four or more antibiotics. In alternative embodiments, these compositions and methods are dosaged and administered to children in need thereof. In alternative embodiments, compositions and methods of the invention are dosaged, formulated and dosaged as tablet, capsule, liquid, powder or aerosol preparations or formulations, or preparations or formulations for oral delivery or inhalation.

The invention relates to the technical field of tracheitis treatment, in particular to a spittoon asthma tablet and a preparation method thereof. The tablets for treating asthma caused by excessive phlegm comprise 60-80 parts of radix sophorae flavescentis extract, 5-10 parts of golden cypress fruit oil, 20-30 parts of filler, 1-2 parts of lubricant, 5-10 parts of lily, 2-5 parts of fried almond and 0.5-1 part of liquorice. The sophora flavescens extract, the cortex phellodendri oil and the lily have a synergistic effect, and after the sophora flavescens extract, the cortex phellodendri oil and the lily are combined, cough and asthma such as chronic tracheitis or bronchitis can be remarkably treated, and the effect is remarkable.

The invention discloses a traditional Chinese medicine compound preparation and a preparation method thereof. The compound preparation is prepared from, by weight, 6-10 parts of herba ephedrae, 9-12 parts of semen armeniacae amarae, 6-9 parts of radix platycodonis, 9-15 parts of cortex mori, 6-10 parts of fritillary bulb, 10-15 parts of thorny elaeagnus leaf, 12-18 parts of herba ardisiae japonicae, 9-12 parts of folium eriobotryae, 15-30 parts of herba houttuyniae, 6-10 parts of caulis bambusae in taeniam, 6-9 parts of pericarpium citri reticulatae, 3-6 parts of spearmint and 3-6 parts of radix glycyrrhizae. The traditional Chinese medicine compound preparation disclosed by the invention creatively integrates the three effects of diffusing the lung, dispelling wind, clearing heat, reducing phlegm, moistening dryness and relieving asthma, and has a good effect in the aspect of treating exogenous cough with symptoms of acute and chronic bronchitis and cough after cold.

The invention belongs to the field of biological medicine, and particularly relates to application of small molecules in prevention and treatment of acute and chronic bronchitis, N-dodecyl methylamine can significantly prolong cough latency time of mice suffering from acute or chronic bronchitis, significantly reduce cough times of the mice suffering from acute or chronic bronchitis, and significantly improve cough latency time of the mice suffering from acute or chronic bronchitis. The micromolecule can be used as a medicine for treating or relieving acute or chronic bronchitis, and a new choice is provided for clinical treatment of bronchitis; double distilled water suspension small molecules are adopted for administration, the method is simple, convenient and rapid, and a remarkable effect is achieved. The micromolecule can obviously reduce the cough frequency and cough latency time of acute and chronic bronchitis, and has a good clinical application prospect.

The present disclosure relates to methods of treatment of asthma, COPD, Asthma-COPD Overlap Syndrome (ACOS), and chronic bronchitis, or a combination thereof, with formulations comprising (S)-3-(3-(1-methyl-2-oxo-5-(pyrazolo[1,5-a]pyridin-3-yl)-1,2-dihydro-3H-imidazo[4,5-b]pyridin-3-yl)piperidin-1-yl)-3-oxopropanenitrile.

The present application relates to a use of L-erodostatin, and more particularly, to a use of erodostatin in preparation of a medicament, wherein the medicament is used for one or more of mucus dissolution and expectoration, treatment or improvement of upper respiratory inflammation, treatment or prevention of acute or chronic bronchitis, treatment or prevention of cough, treatment or prevention of asthma, treatment or prevention of pneumonia, prevention of pulmonary fibrosis, prevention of alveolar destruction, treatment or prevention of chronic obstructive pulmonary disease, enhancement of resistance to bacteria causing upper respiratory infection, and improvement of side effects caused by smoking. The present application can rapidly increase the blood concentration of metabolically active Met-I of erodostatin, exhibit a rapid and excellent effect, and has no toxicity, and has the same effect as the existing racemic compound at a smaller amount. In addition, since the amount used can be less than that of the existing racemic compound, the present application has an effect of reducing potential side effects.

The invention belongs to the technical field of medicines, and particularly discloses a novel 5-7-5 ring system beta acid compound, a preparation method thereof and application of the compound in preparation of anti-inflammatory drugs. The novel 5-7-5 ring system beta acid compound provided by the invention is obtained by separation in nature for the first time, and can be used for preparing medicines for treating inflammation-related diseases, including but not limited to chronic bronchitis, systemic lupus erythematosus, psoriatic arthritis, retinitis, neurological inflammation, rheumatoid arthritis and the like.

The present invention relates to novel pyrrolidinium compounds, stereoisomers thereof, hydrates thereof, or solvates thereof, which exhibit excellent binding ability and antagonistic activity to muscarinic receptors, particularly muscarinic M3 receptors. [Solution] The compounds of the present invention are useful in treating muscarinic acetylcholine receptor-mediated diseases such as hyperhidrosis, excessive salivation, chronic obstructive pulmonary disease, chronic bronchitis, asthma, rhinitis, urinary incontinence, overactive bladder syndrome, gastroesophageal reflux disease, and irritable bowel syndrome.

The invention relates to the technical field of traditional Chinese medicine pharmacy, and particularly discloses a cough and asthma patch and a preparation method thereof. The cough and asthma patch is prepared from active ingredients and a matrix, the active ingredients are prepared from folium eriobotryae, almonds, elaeagnus pungens, actinidia chinensis roots, thyme, polygala japonica, elephantopus scaber, gynura bicolor, veronica didyma, borneol and mentholum, and the matrix is bionic polymeric gel. The preparation method comprises the following steps: S1, preparing the extract; s2, colloid melting: melting the bionic polymer gel; s3, mixing to prepare paste: adding the extract obtained in S1, borneol and mentholum into the molten colloid obtained in S2, and stirring and mixing; and S4, forming. The cough and asthma patch can be used for relieving cough and asthma symptoms caused by asthma and chronic bronchitis, and has the advantages of being rapid in effect taking and lasting in medicine effect; in addition, the preparation method of the cough and asthma patch has the advantages of improving the transfer rate of the active ingredients, the homogeneity of the paste and the low-temperature stability.

Disclosed is a synthetic, non-naturally occurring 12-amino acid peptide, Lung-specific Targeting Peptide, belonging to the larger class of cell penetrating peptides, for delivery of both diagnostic and potentially therapeutic agents to the lung. Also disclosed are methods of treating pulmonary disease, e.g., chronic obstructive pulmonary disease (COPD), emphysema, chronic bronchitis, asthma, primary ciliary dyskinesia (PCD), cystic fibrosis (CF), and lung cancer.

The invention discloses a budesonide modified compound, a pharmaceutical composition and application of the budesonide modified compound, the budesonide modified compound is a compound shown in a formula (I) or a salt of the compound shown in the formula (I), deposition of the budesonide modified compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide modified compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

The utility model discloses a kind of metal frame processing anti-deviation welding equipment, including welding frame, the inside movable mounting of welding frame has reciprocating screw rod, the both sides of reciprocating screw rod are provided with guide vane, the inside movable of welding frame is provided with transmission seat, transmission seat is fixed with welding gun and is inserted in the inside, the end outer side of welding gun is installed with negative pressure hopper, negative pressure hopper includes the fixed disc installed in the end outer side of welding gun, the outside of fixed disc is covered with smoke suction disc, smoke suction disc end is fixedly provided with negative pressure pipe.The metal frame processing anti-deviation welding equipment, smoke suction disc is wide in front and narrow in back, the front end of front width can expand smoke capture range, form larger negative pressure adsorption area near welding gun, effectively cover the smoke diffusion range generated when welding;Reduce workshop smoke escape;Avoid the situation that staff long-term inhalation can cause welder pneumoconiosis, chronic bronchitis, emphysema and other respiratory diseases.

The invention discloses a cold region chronic obstructive pulmonary disease risk prediction method, electronic equipment and a storage medium. The cold region chronic obstructive pulmonary disease risk prediction method comprises the steps of obtaining conventional indexes of a person to be predicted; and inputting the conventional indexes into a preset COPD risk prediction model so as to predict and display the disease risk of the to-be-predicted person. Wherein the conventional indexes comprise age, smoking condition, drinking condition, chronic bronchitis and emphysema history, airflow blocking condition, average diastolic pressure, heart rate and BMI. The conventional indexes can be obtained without depending on expensive special equipment (such as imaging equipment) or complex biomarker detection, so that the data acquisition cost and the operation difficulty are greatly reduced. The preset COPD risk prediction model is constructed based on an XGBoost model and a Logistic Regression model, so that efficient and accurate COPD disease risk prediction can be realized, and the applicability of the model can be improved.

The present invention relates to a metered dose inhaler device comprising a stable inhalable composition of ipratropium bromide, contained in a canister fitted with a metering valve, an actuator and a dose indicator. The present invention also relates to a process for preparing such a pharmaceutical composition and its use in the treatment of respiratory disorders such as for the maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema in a subject in need thereof (e.g., a human).

The invention discloses a budesonide prodrug compound, a pharmaceutical composition and application of the budesonide prodrug compound, the budesonide prodrug compound is a compound shown in the formula (I) or pharmaceutically acceptable salt of the compound shown in the formula (I), deposition of the budesonide prodrug compound in the oropharynx part and the throat part is little, and therefore adverse reactions can be reduced, and the budesonide prodrug compound can be used for preparing medicines. The pharmaceutical composition can be used for treating glucocorticoid-dependent or non-dependent bronchial asthma or asthmatic chronic bronchitis, and can be administered through any proper administration route according to clinical requirements.

Systems and methods involve abrading a patient lung airway wall to reduce mucus production therein. Exemplary techniques include rotationally and / or linearly oscillating an abrasive material against the airway wall so as to damage mucus producing tissues, for example by removing goblet cells, while destroying less than the entire airway wall. The abrasive material may be present on the surface of an expandable balloon body or another expandable device, which can be delivered to the patient treatment site via a bronchoscope. In some cases, the abrasion techniques can cause cell damage or death at a controlled or predetermined tissue depth.

The invention discloses an internal traditional Chinese medicine composition and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine, and the traditional Chinese medicine for pulmonary fibrosis comprises 28-31 g of bletilla striata, 9-11 g of donkey-hide gelatin, 9-11 g of astragalus membranaceus and 4-6 g of pseudo-ginseng. Therefore, the invention provides the traditional Chinese medicine composition for internal use as well as the preparation method and the application thereof, and the traditional Chinese medicine composition for internal use is used for treating chronic gastritis, gastroduodenal ulcer complicated with perforation bleeding; chronic tracheitis, bronchiectasis and bleeding; the traditional Chinese medicine composition has good prevention and treatment effects on both pulmonary fibrosis and lithiasis.

The invention relates to specific polyglycerol derivatives and their further medical uses, namely to dPG / lPG-DTBA and dPG / lPG-cysteamine. These polyglycerol derivatives have a linear or dendritic polyglycerol backbone and carry at least one thiol group covalently bound to the polyglycerol backbone. The claimed medical uses are the use as mucolytic; the use in treating chronic sinusitis, asthma, chronic bronchitis, cystic fibrosis, chronic obstructive pulmonary disease, emphysema, or bronchiectasis; and the use in treating chronic inflammatory bowel diseases, constipation, gastrointestinal malabsorption syndrome, irritable bowel syndrome, steatorrhea or diarrhea.

The invention provides an application of exosomes secreted by autologous stem cell culture in bronchitis COPD treatment, based on an autologous adipose-derived stem cell (ADSCs) organ-like cell directional culture technology, stem cells are induced to be differentiated into bronchial organ-like cells, the exosomes secreted by the bronchial organ-like cells are collected, and the COPD treatment of bronchitis is realized. Through atomization administration, chronic bronchitis, acute bronchitis and chronic bronchitis can be treated. The exosome of the tissue cells of the autologous bronchial mucosa directly reaches the bronchial mucosa through aerosol inhalation, and plays a role through the following ways: anti-inflammation: inhibiting an NF-kappa B pathway, and reducing the release of IL-6 and TNF-alpha; epithelium repair: activating a Wnt / beta-catenin signal to promote basal cell proliferation and enhance a mucus cilia removal function; immunoregulation: regulating and controlling polarization of macrophages to M2 anti-inflammatory phenotype. Therefore, local concentration is high, whole-body side effects are avoided, the whole path of trachea-bronchus-alveolus alveolus is covered, and precise targeted repair is achieved.

The application discloses a kind of compound pharmaceutical composition containing PDE-3 / 4 inhibitor, pharmaceutical preparation and preparation method and application thereof, belong to medical technology field.For the high adverse reaction risk of existing COPD treatment drug, poor patient compliance, heavy economic burden, lack of compound inhalation preparation suitable for severe patients;And the physicochemical properties of different active ingredients are greatly different, it is difficult to stably disperse, PDE-3 / 4 inhibitor wet heat sterilization is easy to generate impurities and other problems.The composition of the application includes PDE-3 / 4 inhibitor, glucocorticoid / JAK inhibitor anti-inflammatory component and LABA / LAMA long-acting bronchodilator.Using polysorbate 80-hydroxypropyl betacyclodextrin stabilizing system, the wet heat sterilization process is optimized, the sterilization concentration is controlled to be 100mg / mL, the process impurities are greatly reduced, the product purity and safety are improved, and sterile inhalation suspension is prepared, which can be atomized to treat chronic bronchitis related COPD.

The present disclosure is directed to an aqueous therapeutic protein formulation including: (i) one or more therapeutic proteins, wherein the one or more therapeutic proteins include one or more anti-DNABII antibodies or antigen-binding fragments thereof in an amount ranging from 10 to 150 mg / mL; (ii) histidine buffer, (iii) NaCl, and (iv) an aqueous carrier, wherein a pH of the aqueous therapeutic formulation ranges from 5.5-8.0, and wherein the formulation is formulated for respiratory tract delivery and produces particles including the one or more therapeutic proteins upon aerosolization. Methods of generating an aerosol and treating biofilm-associated diseases or disorders, e.g., cystic fibrosis, ventilator-associated pneumonia, and acute exacerbations of chronic obstructive pulmonary disease or chronic bronchitis are also provided.

A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.